Operable gastro-oesophageal junctional adenocarcinoma: Where to next?

Table 1 Selected trials of peri-operative therapy for junctional oesophageal adenocarcinoma

Trial	Year	% Junctional adenocarcinoma or lower oesophageal tumours	n	Treatment	Survival(%)
Peri-operative chemotherapy
MAGIC[5]	2006	Adenocarcinoma 100%	503	Surgery	23.00
		Lower oesophageal/GEJ 26%		Peri-operative chemotherapy	36.30 (5-year-OS)
FNCLCC- FFCD[6]	2011	Adenocarcinoma 100%	224	Surgery	24
		Lower oesophagus 11%, GEJ 64%		Peri-operative chemotherapy	38 (5-year-OS)
OEO2[7,8]	2009	Adenocarcinoma 66.5%	802	Surgery	17.10
		Lower 1/3 and cardia 75%		Neoadjuvant chemotherapy	23.00 (5-year-OS)
Pre-operative chemoradiotherapy
Stahl[13]	2009	Adenocarcinoma 100%	126	Neoadjuvant chemotherapy	27.70
		GEJ 100%		Neoadjuvant chemoradiotherapy	47.40 (3-year-OS)
Tepper[14]	2009	Adenocarcinoma 75%	56	Surgery	1.79y
		Distal oesophagus/GEJ 100%		Neoadjuvant chemoradiotherapy	4.48y (median OS)
CROSS[15]	2012	Adenocarcinoma 74%	366	Surgery	44
		Distal 1/3 oesophagus 57, GEJ 24%		Neoadjuvant chemoradiotherapy	58 (3-year-OS)
Post-operative chemoradiotherapy
INT-0116[16]	2001	Adenocarcinoma 100%	556	Surgery	41
		Cardia 20%		Adjuvant chemoradiotherapy	50 (3-year-OS)

DFS: Disease free survival; GEJ: Gastroesophageal junction; OS: Overall survival; SCC: Squamous cell carcinoma.